Compare CLBT & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | LIVN |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | Israel | United Kingdom |
| Employees | 1285 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | N/A | 2015 |
| Metric | CLBT | LIVN |
|---|---|---|
| Price | $12.81 | $79.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.50 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 2.0M | 671.2K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | $9.79 |
| Revenue Next Year | $17.47 | $6.63 |
| P/E Ratio | ★ $45.29 | $199.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.03 | $41.02 |
| 52 Week High | $19.98 | $80.96 |
| Indicator | CLBT | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 65.78 |
| Support Level | $12.65 | $61.63 |
| Resistance Level | $13.95 | N/A |
| Average True Range (ATR) | 0.71 | 2.31 |
| MACD | -0.14 | 0.32 |
| Stochastic Oscillator | 12.03 | 81.36 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.